CSA Medical, Inc. has expanded its truFreeze label with the addition of Barrett’s Esophagus (BE) with low-grade dysplasia.
CSA Medical develops and manufactures a proprietary interventional spray cryotherapy technology platform utilising unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing.
The expansion of the truFreeze label comes after the submission of clinical data supporting the use of truFreeze Spray Cryotherapy in patients with BE and low-grade dysplasia. The Food and Drug Administration (FDA) has now recognised the safety and effectiveness of the trueFreeze system.
... to continue reading you must be subscribed
